Digital health company Trellus Health plc (AIM: TRLS) announced on Wednesday that it has signed a deal with a significant US health plan to manage Inflammatory Bowel Disease (IBD). The agreement spans up to 21 months, focusing on IBD condition management for plan members across two US states through the Trellus Elevate IBD program.

Trellus Health targets the convergence of chronic illness and mental health. The company's proprietary resilience-based methodology, integrated with technology and expert coaching, powers Trellus Elevate, providing a holistic experience for individuals to master their health. The approach aims to relieve disease burden, enhance self-management skills, and foster positive health behaviors, ultimately improving outcomes for chronic conditions.

Founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, Trellus Health initially focuses on high mental health burden GI conditions, such as IBD and Irritable Bowel Syndrome (IBS). The company's comprehensive approach addresses not only symptoms but also promotes overall well-being and human flourishing.

Trellus Elevate leverages a proprietary resilience-driven methodology validated through seven years of clinical research, showcasing significant improvements in patient outcomes and potential cost savings for healthcare payers.